Effect of Fimasartan on Extended RAS and Vascular Functions in Patients With Type 2 Diabetes and Hypertension
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
In this study, we will assess the change of extended renin-angiotensin system including serum
ACE-2 and angiotensin(1-7) levels and subclinical atherosclerosis after using fimasartan (an
ARB), compared to amlodipine in hypertensive patients with T2DM.